Journal article

Plasma ctDNA enables early detection of temozolomide resistance mutations in glioma

JJ Jones, KL Jones, SQ Wong, J Whittle, D Goode, H Nguyen, J Iaria, S Stylli, J Towner, T Pieters, F Gaillard, AH Kaye, KJ Drummond, AP Morokoff

Neuro Oncology Advances | Published : 2024

Abstract

Background. Liquid biopsy based on circulating tumor DNA (ctDNA) is a novel tool in clinical oncology, however, its use has been limited in glioma to date, due to low levels of ctDNA. In this study, we aimed to demonstrate that sequencing techniques optimized for liquid biopsy in glioma patients can detect ctDNA in plasma with high sensitivity and with potential clinical utility. Methods. We investigated 10 glioma patients with tumor tissue available from at least 2 surgical operations, who had 49 longitudinally collected plasma samples available for analysis. Plasma samples were sequenced with CAPP-seq (AVENIO) and tissue samples with TSO500. Results. Glioma-derived ctDNA mutations were det..

View full abstract